Advice
in the absence of a submission from the holder of the marketing authorisation:
sarilumab (Kevzara®) is not recommended for use within NHSScotland.
Indication under review: treatment of polymyalgia rheumatica (PMR) in adult patients who have had an inadequate response to corticosteroids or who experience a relapse during corticosteroid taper.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.
Download detailed advice238KB (PDF)
Medicine details
- Medicine name:
- sarilumab (Kevzara)
- SMC ID:
- SMC2810
- Indication:
Treatment of polymyalgia rheumatica (PMR) in adult patients who have had an inadequate response to corticosteroids or who experience a relapse during corticosteroid taper.
- Pharmaceutical company
- Sanofi
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 12 May 2025